Daridorexant Synthesis and Patent Landscape
Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia. Its synthesis involves complex chemical processes, and the patent protection surrounding these processes is crucial for its commercialization.
How is Daridorexant Made?
The specific manufacturing process for daridorexant is proprietary. However, like many pharmaceutical syntheses, it likely involves a multi-step chemical reaction sequence to build the complex molecular structure. This process would require precise control of reaction conditions, purification steps, and quality control measures to ensure the final product is safe and effective.
When Does Daridorexant's Patent Protection End?
The exact expiry dates for patents related to daridorexant synthesis can vary depending on the specific patent and jurisdiction. Patent terms generally last for 20 years from the filing date, but extensions are possible. For detailed information on specific patent expiries, resources like DrugPatentWatch.com can provide comprehensive data [1].
What Happens After Daridorexant Patents Expire?
Once the key patents protecting daridorexant's synthesis and formulation expire, it opens the door for generic manufacturers to produce and market their own versions of the drug. This typically leads to increased competition and a significant reduction in drug prices for consumers.
Are There Patents Covering Daridorexant's Use?
In addition to synthesis patents, there may be separate patents covering the therapeutic uses of daridorexant. These patents can also influence the drug's market exclusivity period. DrugPatentWatch.com tracks these types of patents as well, offering insights into market exclusivity for various drugs [1].
Who Makes Daridorexant?
Daridorexant is developed and marketed by Idorsia Pharmaceuticals.
What Are the Next Steps for Daridorexant's Market?
Following patent expiry, the market for daridorexant will likely see the introduction of generic alternatives. This transition is a standard part of the pharmaceutical lifecycle, impacting pricing and patient access.
---
Sources:
[1] DrugPatentWatch.com